Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, December 18, 2018 · 471,472,370 Articles · 3+ Million Readers

Anti-Infective Drugs' Largest Market Grinds To A Halt

Global Anti-Infective Drugs Market By Region

Global Anti-Infective Drugs Market By Region

LONDON, GREATER LONDON, UK, October 19, 2017 / -- In North America, which accounts for over 30% of the global market, sales of drugs to treat or prevent infectious diseases are rising at a negligible 0.1% year on year. Another large market, Western Europe, is also growing slowly at a meagre 2.35% annually. Sales in South America and Africa are booming, rising at an annual 8.7% and 8.9% respectively, but these are small markets. The only substantial high growth market region is Asia Pacific, accounting for 20% of the global total and growing at 7% a year. Thus Asia Pacific is the region that presents the best opportunities for manufacturers of anti-infective drugs, although competition in the region is fierce: sales of low-priced generic versions of out-of-patent drugs are highly significant.
The global growth of the anti-infective drugs market, held back by the slow rise in the largest regions, is around 3% a year.
Infectious diseases are disorders caused by pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct or indirect contact. Anti-infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal). The main anti-infective drugs include antibiotics, antifungals, antimalarial agents, antituberculosis agents, antiviral agents, penicillins, sulfonamides and tetracyclines.
In the developed world, the incidence of the major kinds of lethal infectious illness has subtantially reduced despite periodic viral epidemics such as 'flu and the recent return of tuberculosis affecting small numbers of patients. That helps explain the low rate of growth of the anti-infective drugs market in North America and Western Europe and why the opportunities for anti-infective drugs manufacturers there are limited. In the less developed world, fatal diseases such as malaria still have high prevalence, while climatic conditions encourage fungal and bacterial illness. This helps account for the high growth rates for anti-infective drugs in South America, Africa and Asia Pacific.
USA pharmaceuticals companies Gilead Sciences and Merck are the market leaders in anti-infective drug sales, followed by the British drug manufacturer GlaxoSmithKline. Just under 60% of the global total is split among small producers outside the top ten in the market.
One of the trends shaping the market is an increased demand for new medicines for drug-resistant infections. The demand for new drug candidates for antimicrobial resistant infections is increasing. Antimicrobial resistance is a serious concern to global public health as it resulted in long duration of illness, the requirement of additional tests and use of more expensive drugs. Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, parasites and fungi change and adapted to drugs when they are exposed to antimicrobial drugs such as antibiotics, antivirals, antifungals, anthelmintics and others. According to World Health Organization (WHO), globally 4,80,000 people are developing multi-drug resistant TB each year and drug resistance is starting to complicate the treatment of malaria and HIV as well. Companies are investing in developing the new drug candidates to treat drug-resistant infections. For instance, in 2014, Cubist Pharmaceuticals launched a new antibiotic Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal infections, complicated urinary tract infections and also for infections of the kidney (pyelonephritis) . Also, Johnson & Johnson launched Sirturo (bedaquiline) for pulmonary multi-drug resistant tuberculosis. In November 2013, Roche and Polyphor Ltd have entered into a licensing agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080 for the treatment of Pseudomonas aeruginosa bacterial infections which become resistant to many antibiotic treatments.

Where to Learn More
Read Anti-infective Drugs Market Global Report 2017 from The Business Research Company for information on the following:
Markets Covered: Antibiotics, Antivirals, Antifungals, Others (Antihelmethic, Antiprotozoal)
Companies Mentioned: Pfizer Inc., GlaxosmithKline, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Interested to know more? Here is a full scope of Biologics and Pharmaceutical Drugs Market reports to explore:
1. Biologics Market Global Report 2017 (
2. Pharmaceutical Drugs Market Report 2017 (
3. Cardiovascular Drugs Market Global Report 2017 (
4. Central Nervous System Drugs Market Global Report 2017 (
5. Dermatology Drugs Market Global Report 2017 (
6. Genito-Urinary Drugs Market Global Report 2017 (
7. Hematology Drugs Market Global Report 2017 (
8. Metabolic Disorder Drugs Market Global Report 2017 (
9. Musculoskeletal Disorders Drugs Market Global Report 2017 (
10. Ophthalmology Drugs Market Global Report 2017 (
11. Gastrointestinal Drugs Market Global Report 2017 (
12. Respiratory Drugs Market Global Report 2017 (
13. Oncology Drugs Market Global Report 2017 (

About The Business Research Company
Visit The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company’s management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations. The Business Research Company’s Consultant have master’s qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company’s Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.

Oliver Guirdham
The Business Research Company
+44 744 3439350
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release